Poster Sessions

Poster Session B
Friday, March 1: 11:30 AM-1:00 PM and 5:30 PM-6:30 PM

Trials in Progress Poster Session B
Friday, March 1: 11:30 AM-1:00 PM and 5:30 PM-6:30 PM

Posters by Topic

Breast and Gynecologic Cancers: Poster Boards A7-A8, B1-B6
Combination Studies: Poster Boards A1-A2
Developmental Therapeutics: Poster Boards A5-A6
Gastrointestinal Cancer: Poster Boards B7-C9
Genitourinary Cancer: Poster Boards D1-D9
Head and Neck Cancers: Poster Boards D10-E4
Hematologic Malignancies: Poster Board A9
Miscellaneous Cancers: Poster Boards A3-A4, G2-H1
Melanoma/Skin Cancers: Poster Boards A4, E5-G1
Trials in Progress: Poster Boards H2- H9

BOARD A1
Abstract 11: Phase Ib/II trial of lenvatinib plus pembrolizumab in urothelial cancer.
First Author: Nicholas Vogelzang, MD, FASCO, FACP


BOARD A2
Abstract 12: A phase Ia/Ib study of an anti-TIM-3 antibody (LY3321367) monotherapy or in combination with an anti-PD-L1 antibody (LY3300054): Interim safety, efficacy, and pharmacokinetic findings in advanced cancers.
First Author: James Harding, MD


BOARD A3
Abstract 147: Antibiotic treatment prior to immune checkpoint inhibitor therapy as a tumor-agnostic predictive correlate of response in routine clinical practice.
First Author: David Pinato, MD, PhD, MRCP


BOARD A4
Abstract 130: Liquid biopsy using plasma proteomic profiling to reveal predictors of immunotherapy response.
First Author: Arnav Mehta, MD, PhD


BOARD A5
Abstract 26: Phase Ib: Preliminary clinical activity and immune activation for NKTR-262 [TLR 7/8 agonist] plus NKTR-214 [CD122-biased agonist] in patients (pts) with locally advanced or metastatic solid tumors (REVEAL Phase Ib/II Trial).
First Author: Adi Diab, MD


BOARD A6
Abstract 27: Tumor Mutational Burden (TMB): Assessment of inter- and intra-tumor heterogeneity.
First Author: Jeffrey Conroy


BOARD A7
Abstract 1: Final analysis of Nelipepimut-S plus GM-CSF with trastuzumab versus trastuzumab alone to prevent recurrences in high-risk, HER2 low-expressing breast cancer: A prospective, randomized, blinded, multicenter phase IIb trial.
First Author: Annelies Hickerson, MD


BOARD A8
Abstract 2: Phase I study of the safety and activity of formulated IL-12 plasmid administered intraperitoneally in combination with neoadjuvant chemotherapy in patients with newly diagnosed advanced stage ovarian cancer.
First Author: Premal Thaker, MD


BOARD A9
Abstract 74: Enhanced antitumor effect and lower viral reactivation with high doses of ex vivo expanded NK cells administered after haploidentical transplantation.
First Author: Stefan Ciurea, MD


BOARD B1
Abstract 3: Upregulation of programmed death ligand 1 (PD-L1) on circulating epithelial tumor cells (CETCs) as consequence of adjuvant radiation therapy in primary breast cancer patients.
First Author: Monika Pizon


BOARD B2
Abstract 4: A phase II trial with the combination of plinabulin (plin) pegfilgrastim (peg): Evaluation of the reversal of peg’s immune-suppressive potential by the addition of plin to peg.
First Author: Douglas Blayney, M.D.


BOARD B3
Abstract 5: Production of autologous monocytes stimulated ex vivo with peg-interferon alfa 2b and interferon gamma 1b for intraperitoneal administration in phase I clinical trial.
First Author: Anna Duemler, BS


BOARD B4
Abstract 6: Targeted tumor-derived cellular immunotherapy in advanced breast cancer patients induces initial immune responses and tumor regression.
First Author: Vivekananda Sunkari, Ph.D.


BOARD B5
Abstract 7: Understanding the peripheral cellular immunome in patients with breast cancer.
First Author: Karenia Landa, MD


BOARD B6
Abstract 8: RNA-sequencing reveals immunotherapy targets in gynecological cancer.
First Author: Antonios Papanicolau-Sengos, MD, MS


BOARD B7
Abstract 43: Tumor mutational burden (TMB) may be a promising predictive biomarker of response to PD-1/PD-L1 targeting in MSI-H colorectal cancer.
First Author: Marwan Fakih, MD


BOARD B8
Abstract 44: Histology could predict a “hot” or a “cold” gastric tumor?
First Author: Ina Valeria Zurlo, MD


BOARD B9
Abstract 45: Epigenetic biomarkers for noninvasive detection of colorectal cancer.
First Author: Dhruvajyoti Roy


BOARD B10
Abstract 46: A comparison of microsatellite instability analysis methods in colorectal cancer.
First Author: Samantha Lewis, PhD


BOARD C1
Abstract 47: Paradoxical effect of regulatory T cell density in the invasive margin on colon cancer disease-free survival.
First Author: Jamie Lombardo, MD


BOARD C2
Abstract 48: Results of a phase II study evaluating trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
First Author: Manish Patel, MD


BOARD C3
Abstract 49: Analysis of colorectal cancer patients treated on ETCTN 10021: A multicenter randomized trial of combined PD-L1 and CTLA-4 inhibition with targeted low-dose or hypofractionated radiation.
First Author: Arta Monjazeb, MD, PhD


BOARD C4
Abstract 50: Low molecular weight heparin (LMWH) enhances immunotherapy (I) activity in pancreatic cancer cells.
First Author: Michalis Karamouzis, MD, PhD


BOARD C5
Abstract 51: Association of intratumoral FoxP3 T-regulatory lymphocytes and perineural invasion in colorectal adenocarcinoma.
First Author: Lynn Messersmith, DO


BOARD C6
Abstract 52: Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC.
First Author: Ahmed Kaseb, MD


BOARD C7
Abstract 53: Investigating the tumor-immune microenvironment in an autochthonous murine model of cholangiocarcinoma.
First Author: Booyeon Han


BOARD C8
Abstract 54: Breaking immune tolerance for the treatment of pancreatic cancer: Phase I/II clinical experience.
First Author: David Nam, BS


BOARD C9
Abstract 55: iRGD in combination with IL-2 reprograms tumor immunosuppression.
First Author: Gregory Botta, MD, PhD


BOARD D1
Abstract 58: Differences in immune tumor microenvironment between primary and metastatic castration-resistant prostate cancer.
First Author: Yuanquan Yang, MD, PhD


BOARD D2
Abstract 59: Role for immune checkpoint blockade in BRCA2-mutant prostate cancer.
First Author: Anshuman Panda, PhD


BOARD D3
Abstract 60: Developing a new urine cell flow cytometry analysis of PD-L1 expression and DNA content for diagnosis of bladder cancer.
First Author: Shaheen Alanee, MD, FACS, MBA, MPH, FRCS


BOARD D4
Abstract 61: Cell proliferation as a biomarker for response to immune checkpoint inhibitors in highly inflamed renal cell carcinoma.
First Author: Sarabjot Pabla, PhD, MSc, BSc


BOARD D5
Abstract 62: Cell proliferation as a biomarker for response to immune checkpoint inhibitors in PD-L1 negative renal cell carcinoma.
First Author: Sean Glenn


BOARD D6
Abstract 63: Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor (ICI) response in metastatic renal cell carcinoma (mRCC).
First Author: Jason Zhu, MD


BOARD D7
Abstract 64: Modeling of prognostication based on genomic expression in the tumor microenvironment of muscle invasive urothelial carcinoma via machine learning.
First Author: Sunyoung Lee, MD, PhD


BOARD D8
Abstract 65: Effect of age and gender on expression levels of markers of immune cell infiltration and immune checkpoint pathways in patients with muscle-invasive transitional cell carcinoma of the bladder: A retrospective study of 50 patients treated with radical cystectomy.
First Author: Shaheen Alanee, MD, FACS, MBA, MPH, FRCS


BOARD D9
Abstract 66: Efficacy of first-line immune checkpoint inhibitors in patients with sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC).
First Author: Ziad Bakouny, MD, MD, MD, MSc, MSc


BOARD D10
Abstract 68: Relationship between tumor burden to growth rate and treatment outcomes of nivolumab for patients with head and neck squamous carcinoma.
First Author: Chiaki Suzuki, MD


BOARD E1
Abstract 69: PD-1 blockade after PD-(L)1 inhibitors in head and neck cancer: Role of immunotherapy rechallenge.
First Author: Santiago Cabezas-Camarero, MD


BOARD E2
Abstract 70: Regulatory T cells mediate resistance to radiotherapy in head and neck squamous cell carcinoma.
First Author: Ayman Oweida, PhD


BOARD E3
Abstract 71: Breaking immune tolerance for the treatment of glioblastoma: Phase IIb clinical trial experience.
First Author: Larn Hwang, PhD


BOARD E4
Abstract 72: The anti-tumor effect of oral cancer vaccine using Bifidobacterium as a platform for displaying Wilms’ tumor 1 protein.
First Author: Hikaru Minagawa


BOARD E5
Abstract 131: Biomarkers to predict immune-related adverse events with checkpoint inhibitors.
First Author: Lia Head, MD


BOARD E6
Abstract 132: Th17 responses to autologous dendritic cell vaccine.
First Author: Gabriel Nistor, MD


BOARD E7
Abstract 133: Prognostic models for advanced melanoma patients treated with anti-PD-1 monotherapy.
First Author: Xue Bai, MD


BOARD E8
Abstract 134: Peripheral blood TCRB chain convergence and clonal expansion following cytomegalovirus infection: Implications for the biomarker use of TCR-seq.
First Author: Timothy Looney, PhD


BOARD E9
Abstract 135: Hematological profile: A prognosis tool in melanoma patients treated with immunotherapy.
First Author: Soraia Lobo Martins, MD


BOARD F1
Abstract 136: Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients previously treated with at least one prior systemic therapy.
First Author: Amod Sarnaik, MD


BOARD F2
Abstract 137: Healthcare resource utilization in first-line immunotherapies for patients with metastatic melanoma.
First Author: Frank Xiaoqing Liu, PhD


BOARD F3
Abstract 138: Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients.
First Author: Jesus Vera Aguilera, MD


BOARD F4
Abstract 139: Emerging treatment patterns and checkpoint inhibitor (CPI) use among newly diagnosed Merkel cell carcinoma (MCC) patients in the United States veteran population.
First Author: Ying Zheng


BOARD F5
Abstract 140: Response rate and safety of standard-dose nivolumab with reduced-dose ipilimumab in metastatic melanoma.
First Author: Inderjit Mehmi


BOARD F6
Abstract 141: Real-world time to next treatment (TTNT) for first-line (1L) targeted and immuno-oncology therapies for BRAF-mutated metastatic melanoma (MM) by lactate dehydrogenase (LDH) level.
First Author: Jason Luke, MD, FACP


BOARD F7
Abstract 142: Checkpoint inhibitor (CPI) experienced patients (pts) from COSMUS-1: A clinical observational study of talimogene laherparepvec (T-VEC) in United States practice.
First Author: Matthew Perez, MD


BOARD F8
Abstract 143: Effect of radiofrequency ablation (RFA) combined with anti-CTLA-4 and anti-PD1 in a preclinical melanoma model.
First Author: Olga Franco-Mahecha, DVM. PhD


BOARD G1
Abstract 144: Autoimmune toxicities with anti-PD-1 treatment of metastatic melanoma in predominantly older patients: A single institutional experience.
First Author: Harsh Parmar, MD


BOARD G2
Abstract 148: Association between sample characteristics and tumor mutational burden estimated by next-generation sequencing-based multiplex gene panel assay.
First Author: Quy Pham Nguyen, M.D., Ph.D.


BOARD G3
Abstract 149: MHC-1 genotype as a predictor of response to immunotherapy.
First Author: Aaron Goodman, MD


BOARD G4
Abstract 150: Use of TMB and PD-L1 to predict outcomes of checkpoint inhibitor treatment.
First Author: Paul Robbins, PhD


BOARD G5
Abstract 151: Analysis of real-world PD-L1 IHC testing for clinical use in patients across multiple tumor types.
First Author: Gabriel Krigsfeld


BOARD G6
Abstract 152: Isolation and characterization of exosomes from IDH mutant gliomas.
First Author: Nils Ludwig, DMD


BOARD G7
Abstract 153: Survey of the immunogenomic landscape of solid tumors through clinical DNA and RNA sequencing.
First Author: Denise Lau, PhD


BOARD G8
Abstract 154: Hyperprogressive disease on immune checkpoint therapy in advanced solid malignancies: A systematic review.
First Author: Xiao Wei, MD


BOARD G9
Abstract 155: Infections in patients receiving immune checkpoint inhibitors.
First Author: Sutthichai Sae-Tia, M.D.


BOARD H1
Abstract 156: RRx-001 is a phase III aerospace-derived small molecule that immunonormalizes the tumor microenvironment.
First Author: Pedro Cabrales, PhD


BOARD H3
Abstract TPS10: Randomized phase II trial of patient-specific dendritic cell vaccines loaded with autologous tumor antigens versus autologous monocytes in patients with primary advanced ovarian cancer.
First Author: Robert Dillman, MD


BOARD H4
Abstract TPS56: A phase Ib trial of cabozantinib in combination with durvalumab (MEDI4736) in previously treated patients with advanced gastroesophageal cancer and other gastrointestinal (GI) malignancies (CAMILLA).
First Author: Anwaar Saeed, MD


BOARD H5
Abstract TPS57: Phase I/II trial of BMS-986205 and nivolumab as first-line therapy in hepatocellular carcinoma.
First Author: Justin Chen, MD


BOARD H6
Abstract TPS67: Prevalence of PD-L1 expression in first-line (1L) locally advanced/unresectable or metastatic urothelial carcinoma (UC).
First Author: Petros Grivas, MD, PhD


BOARD H7
Abstract TPS73: Phase I study of durvalumab and tremelimumab together with radiotherapy for the adjuvant treatment of intermediate-risk head and neck squamous cell carcinoma.
First Author: Siddharth Sheth, DO, MPH


BOARD H8
Abstract TPS145: Phase III KEYNOTE-716 study: Adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma.
First Author: Jason Luke, MD, FACP


BOARD H9
Abstract TPS146: Stool donor qualification and collection from metastatic melanoma (MM) patients (pts) who have responded to checkpoint inhibitors (CPI) for manufacturing of fecal microbiota transplantation (FMT).
First Author: Elizabeth Burton, MBA